Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Inclusion Criteria: Must have locally advanced or metastatic ccRCC and have progressed or relapsed after at least 1 prior anti-VEGF/VEGFR systemic therapy and 1 ICI. Measurable disease per the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) KPS score of at least 70% Able to swallow oral medications. Exclusion Criteria: Active CNS metastases and/or carcinomatous meningitis Has had any major cardiovascular event within 6 months or clinically significant cardiovascular disease Major surgery (eg, GI surgery, removal or biopsy of brain metastasis) within 3 months before administration of study drug. Has known HIV History of hepatitis B or known active hepatitis C infection Has received prior treatment with NKT2152, other HIF2α inhibitors, other CDK 4/6 inhibitors, palbociclib, or sasanlimab Radiation therapy for bone metastasis within 2 weeks, or any other external radiation therapy within 4 weeks before administration of the first dose of study treatment Corrected QT interval calculated by Fridericia formula (QTcF) > 480 ms within 28 days prior to first dose Hypoxia or requires intermittent or chronic supplemental oxygen or any chronic lung condition which has required supplemental oxygen in the past Has a history of interstitial lung disease Has any active or recent history of a known or suspected autoimmune disease